Not surprising that Leronlimab couldn't save everyone in this S/C group but every one of them at one time was a mild to moderate case.

If you want to save everyone, they should be given Leronlimab as soon as possible. It should be the SOC for everyone NOW. Its safety alone recommends it and the cost of shorter hospital stays pays for it. It is also the best hope out there for preventing Longhaulers.

As I see it, among Longhaulers there will be three groups - those who will have been damaged by microclots and Leronlimab may not be able to help them, those who may have hidden reservoirs of virus and Leronlimab is their best shot at stopping ongoing morbidities caused by that and there are the ones who have compromised immune systems and could be greatly helped by having their immune system restored to homeostasis.

But, again, every Longhauler started out as a Mild to Moderate case. What are the costs of not preventing this population from getting to this stage?

Can there be any doubt what-so-ever that Leronlimab is the best therapeutic out there? Good luck to the vaccines and mabs that go after the virus itself but Leronlimab is now their proven backstop!